ARCT
Price
$9.84
Change
-$0.89 (-8.29%)
Updated
Oct 23 closing price
Capitalization
279.68M
16 days until earnings call
Intraday BUY SELL Signals
CRSP
Price
$49.39
Change
-$0.60 (-1.20%)
Updated
Oct 23 closing price
Capitalization
4.78B
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs CRSP

ARCT vs CRSP Comparison Chart in %
View a ticker or compare two or three
VS
ARCT vs. CRSP commentary
Oct 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and CRSP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARCT with price predictions
Oct 23, 2026

ARCT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where ARCT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ARCT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.628) is normal, around the industry mean (3.043). P/E Ratio (-2.955) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CRSP with price predictions
Oct 23, 2026

CRSP sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for CRSP moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 65 cases where CRSP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 209 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for CRSP entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.734) is normal, around the industry mean (3.043). P/E Ratio (-10.486) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CRSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARCT vs CRSP: Fundamental Ratings
ARCT
CRSP
OUTLOOK RATING
1..100
776
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
3961
P/E GROWTH RATING
1..100
9449
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (22) in the Biotechnology industry is in the same range as ARCT (33) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to ARCT’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to ARCT’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as ARCT (98) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as CRSP (61) in the Biotechnology industry. This means that ARCT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for ARCT (94) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew somewhat faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCRSP
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
76%
COMPARISON
Comparison
Oct 24, 2026
Stock price -- (ARCT: $9.84 vs. CRSP: $49.39)
Brand notoriety: ARCT and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 43% vs. CRSP: 76%
Market capitalization -- ARCT: $279.68M vs. CRSP: $4.78B
ARCT [@Biotechnology] is valued at $279.68M. CRSP’s [@Biotechnology] market capitalization is $4.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 1 FA rating(s) are green while CRSP’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 1 green, 4 red.
According to our system of comparison, CRSP is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 3 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 3 bullish, 5 bearish.
  • CRSP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ARCT and CRSP are a bad buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а -4.84% price change this week, while CRSP (@Biotechnology) price change was +0.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 09, 2026.

CRSP is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARCT
Daily Signal:
Gain/Loss:
CRSP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLAX33.620.20
+0.60%
Franklin FTSE Asia ex Japan ETF (FLAX)
MIGO29.48N/A
N/A
MIG Core ETF (MIGO)
BITY26.93-0.05
-0.20%
Amplify Bitcoin 2% Monthly Option Income ETF (BITY)
BFEB53.93-0.22
-0.40%
Innovator U.S. Equity Buffer ETF - February (BFEB)
DUHP42.14-0.37
-0.87%
U.S. High Relative Profitability Portfolio: ETF Class Shares (DUHP)
Interesting Articles